On January 13, 2016, the tenth and final subject received their first treatment in our Israeli Phase 2 study of MDMA-assisted psychotherapy for PTSD. Led by Principal Investigator Moshe Kotler, M.D., this Phase 2 study will treat 10 subjects with chronic, treatment-resistant PTSD from any cause. Once the final treatments and evaluations are complete, we will gather data for inclusion in an international meta-analysis of the safety and efficacy of MDMA-assisted psychotherapy for the treatment of PTSD.
